newli
emerg
infecti
diseas
middl
east
respiratori
syndrom
mer
first
identifi
saudi
arabia
report
least
countri
middl
east
europ
africa
asia
north
america
http
wwwcdcgovcoronavirusm
rais
worldwid
concern
pandem
potenti
decemb
mer
coronaviru
merscov
caus
agent
mer
infect
peopl
caus
least
relat
death
mortal
rate
http
merscov
util
bat
camel
natur
reservoir
intermedi
transmiss
host
merscov
spread
close
contact
airborn
transmiss
caus
seriou
public
health
develop
effect
vaccin
strategi
prevent
merscov
infect
diseas
urgent
merscov
spike
protein
play
import
role
viru
attach
subsequ
entri
permiss
cell
express
function
receptor
dipeptidyl
peptidas
receptorbind
domain
rbd
resid
within
subunit
protein
mediat
virusreceptor
bind
therebi
serv
import
target
vaccin
develop
merscov
infect
previous
identifi
rbdencod
residu
includ
residu
fragment
compos
residu
shown
contain
critic
neutral
specif
recent
demonstr
recombin
protein
contain
residu
fuse
fc
human
igg
design
particularli
potent
elicit
neutral
antibodi
immun
mice
addit
incub
permiss
vero
cell
recombin
protein
effect
prevent
merscov
togeth
result
suggest
protein
ideal
subunit
vaccin
candid
worthi
develop
mer
vaccin
compar
vaccin
format
inactiv
viru
liveattenu
viru
viral
vectorbas
subunit
vaccin
recombin
proteinbas
subunit
vaccin
best
safeti
profil
due
virtual
nonexist
concern
possibl
incomplet
inactiv
regain
virul
attenu
viru
unfavor
host
respons
viral
addit
effect
recombin
proteinbas
subunit
vaccin
advantag
specif
target
welldefin
neutral
howev
rel
low
immunogen
recombin
proteinbas
subunit
vaccin
especi
formul
without
adjuv
compar
inactiv
liveattenu
virus
repres
major
hurdl
develop
safe
effect
subunit
well
accept
adjuv
gener
play
essenti
role
enhanc
host
immun
respons
especi
proteinbas
subunit
vaccin
differ
adjuv
could
promot
differ
host
immun
respons
exampl
freund
adjuv
oil
emuls
may
induc
strong
immun
respons
suitabl
human
use
aluminum
salt
alum
licens
human
use
adjuv
unit
state
effici
enhanc
humor
cellular
immun
respons
import
combat
viral
adjuv
system
new
gener
tolllik
receptor
tlr
base
adjuv
combin
agonist
mpl
lipid
alum
licens
use
human
papillomaviru
vaccin
consist
tocopherol
squalen
polysorb
approv
use
human
influenza
viru
vaccin
http
monophosphoryl
lipid
mpla
adjuv
extract
lipopolysaccharid
may
enhanc
immun
respons
induc
influenza
vaccin
superior
alum
cancer
hbv
malaria
hpv
vaccin
achiev
consist
prepar
mplaformul
vaccin
remain
montanid
adjuv
approv
use
human
europ
shown
promot
antigenspecif
antibodi
respons
strong
neutral
activ
varieti
anoth
adjuv
licens
human
use
europ
wellestablish
abil
promot
immunogen
influenza
viru
vaccin
safeti
profil
human
popul
compar
alum
montanid
addit
increas
immunogen
seen
influenza
viru
vaccin
elderli
peopl
compar
convent
subunit
studi
elucid
effect
variou
adjuv
induct
host
immun
respons
merscov
rbdbase
subunit
vaccin
use
protein
model
antigen
specif
compar
merscovspecif
humor
immun
respons
neutral
antibodi
well
cellmedi
immun
respons
elicit
mice
immun
differenti
formul
vaccin
result
show
use
adjuv
potent
optim
merscov
rbdbase
subunit
vaccin
respons
four
eightweekold
femal
balbc
mice
use
studi
anim
studi
carri
strict
accord
recommend
guid
care
use
laboratori
anim
nation
institut
health
anim
protocol
approv
committe
ethic
anim
experi
new
york
blood
center
permit
number
institut
anim
care
use
committe
univers
iowa
protocol
aluminium
hydroxid
gel
alhydrogel
hereinaft
name
alum
mpla
minnesota
mplasm
purchas
invivogen
san
diego
ca
usa
freund
montanid
hereinaft
name
adjuv
product
sigma
st
loui
mo
usa
seppic
fairfield
nj
usa
respect
adjuv
made
mix
squalen
span
tween
sigma
nm
sodium
citrat
ph
follow
sonic
min
solut
filter
filter
store
use
recombin
rbd
protein
select
test
effect
adjuv
construct
express
purif
describ
briefli
codonoptim
gene
encod
residu
merscov
spike
protein
fuse
fc
human
igg
invivogen
result
protein
express
tcell
cultur
supernat
purifi
protein
affin
chromatographi
ge
healthcar
piscataway
nj
usa
elisa
coat
antigen
merscov
protein
residu
plu
ctermin
construct
use
express
vector
jiangsu
taizhou
haiyuan
protein
biotech
co
ltd
taizhou
china
express
tcell
cultur
supernat
purifi
use
ninta
superflow
qiagen
valencia
ca
usa
done
follow
previous
optim
protocol
briefli
balbc
mice
subcutan
vaccin
pb
presenc
equal
volum
adjuv
recommend
manufactur
boost
twice
immunogen
respect
adjuv
interv
protein
pb
includ
control
sera
collect
immun
day
posteach
vaccin
assess
merscov
total
neutral
antibodi
respons
immun
mice
sacrif
day
last
immun
splenocyt
collect
detect
merscov
tcell
respons
specif
immun
schedul
shown
figur
challeng
experi
sensit
mice
merscov
infect
transduc
mice
recombin
nonrepl
adenoviru
express
previous
briefli
balbc
mice
immun
pb
control
plu
adjuv
use
protocol
describ
ten
day
last
immun
mice
transduc
intranas
challeng
pfu
merscov
day
later
mous
lung
tissu
harvest
day
postchalleng
viru
titer
determin
plaqu
assay
figur
elisa
use
measur
murin
antibodi
respons
induc
plu
differ
adjuv
base
previous
describ
briefli
elisa
plate
precoat
merscov
protein
overnight
follow
addit
serial
dilut
sera
incub
h
four
wash
pbst
plate
incub
horseradish
peroxidaseconjug
antimous
igg
ge
healthcar
invitrogen
carlsbad
ca
usa
respect
h
wash
four
time
reaction
visual
substrat
invitrogen
stop
n
absorb
nm
measur
elisa
plate
reader
tecan
san
jose
ca
usa
cell
respons
immun
mice
detect
intracellular
cytokin
stain
follow
flow
cytometri
analysi
previous
describ
briefli
splenocyt
stimul
without
merscov
protein
phorbol
myrist
acet
ngml
ionomycin
sigmaaldrich
st
loui
mo
usa
use
posit
control
cell
stimulatori
agent
incub
h
presenc
golgiplug
contain
brefeldin
bd
bioscienc
san
jose
ca
usa
cell
stain
conjug
apc
min
wash
cell
fix
use
cytofixcytoperm
kit
accord
manufactur
protocol
bd
bioscienc
stain
fitc
pe
bd
bioscienc
min
appropri
isotypematch
control
includ
stain
stain
cell
analyz
use
fac
calibur
bd
bioscienc
facsdiva
softwar
bd
bioscienc
standard
microneutr
assay
use
determin
antimerscov
neutral
briefli
serial
dilut
mous
sera
incub
h
room
temperatur
infecti
transfer
tissu
cultur
plate
contain
vero
cell
h
incub
neutral
capac
individu
sampl
assess
determin
presenc
absenc
virusinduc
cytopath
effect
neutral
antibodi
titer
express
reciproc
highest
dilut
serum
complet
inhibit
virusinduc
cytopath
effect
least
well
valu
present
mean
standard
deviat
sd
statist
signific
among
differ
vaccin
group
calcul
student
ttest
use
graphpad
prism
statist
softwar
p
valu
less
consid
statist
signific
induct
specif
igg
antibodi
respons
fcfuse
merscov
rbd
protein
first
evalu
subsequ
abil
freund
alum
mplasm
augment
merscov
rbdinduc
igg
antibodi
respons
compar
accomplish
mice
immun
presenc
absenc
adjuv
sera
collect
day
day
vaccin
accord
vaccin
schedul
shown
figur
shown
figur
background
immun
respons
observ
mice
immun
first
dose
absenc
adjuv
slightli
elev
antibodi
respons
induc
plu
adjuv
level
respons
increas
second
immun
reach
higher
level
third
immun
immunogen
addit
adjuv
improv
immunogen
vari
extent
evidenc
specif
antibodi
titer
depend
type
adjuv
use
among
adjuv
test
appear
potent
promot
specif
igg
antibodi
respons
titer
reach
significantli
higher
level
induc
adjuv
p
two
immun
absenc
adjuv
alon
induc
antibodi
respons
two
three
immun
suggest
fc
fragment
fuse
rbd
protein
potenti
immun
respons
induc
rbdbase
vaccin
expect
mock
immun
pb
result
induct
detect
merscovspecif
antibodi
figur
also
test
sera
obtain
third
immun
bind
capac
merscov
protein
shown
figur
addit
adjuv
vaccin
formul
improv
bind
specif
protein
potent
promot
activ
base
endpoint
antibodi
titer
assay
note
mice
immun
elicit
significantli
higher
antibodi
respons
immun
protein
adjuv
freund
alum
also
note
mplasmadjuv
induc
significantli
higher
merscovspecif
igg
antibodi
titer
alumadjuv
one
figur
mock
pb
vaccin
mice
fail
induc
specif
igg
antibodi
respons
result
suggest
immunogen
mice
addit
aforement
adjuv
especi
greatli
enhanc
capac
promot
specif
antibodi
respons
next
evalu
abil
induc
specif
igg
subtyp
antibodi
presenc
absenc
adjuv
use
sera
collect
day
third
immun
absenc
adjuv
alon
could
induc
readili
detect
merscov
antibodi
slight
bia
toward
respons
figur
howev
addit
given
adjuv
test
modul
igg
subtyp
respons
specif
note
unlik
adjuv
includ
freund
alum
mplasm
none
promot
respons
usag
adjuv
significantli
enhanc
subtyp
antibodi
figur
b
despit
failur
promot
subtyp
respons
freund
adjuv
like
could
significantli
increas
antibodi
respons
figur
analysi
antibodi
respons
reveal
mice
immun
similar
immun
alon
exhibit
specif
igg
antibodi
respons
slightli
bias
wherea
immun
alum
particularli
mplasmadjuv
protein
strongli
elicit
bias
respons
figur
taken
togeth
among
adjuv
test
seem
potent
adjuv
augment
specif
antibodi
respons
elicit
merscov
rbd
subunit
vaccin
enabl
induct
strong
gener
igg
subtyp
antibodi
respons
abil
fcfuse
merscov
rbd
subunit
vaccin
induc
specif
tcell
respons
evalu
specif
compar
capabl
freund
alum
mplasm
improv
merscov
rbdinduc
cellular
respons
accomplish
mous
splenocyt
collect
day
third
immun
frequenc
cell
enumer
fac
analysi
shown
figur
alon
capabl
induc
merscov
tcell
respons
evidenc
particularli
express
ad
adjuv
test
includ
freund
alum
mplasm
significantli
increas
number
cell
figur
number
cell
figur
anticip
pbsvaccin
mice
induc
specif
tcell
respons
beyond
background
level
figur
result
suggest
none
adjuv
test
could
significantli
enhanc
tcell
respons
induc
assess
abil
fcfuse
merscov
rbd
protein
ie
combin
adjuv
induc
neutral
antibodi
merscov
use
serum
specimen
collect
day
third
immun
describ
earlier
specif
standard
neutral
assay
perform
microtit
plate
use
vero
cell
found
immun
protein
alon
capabl
induc
neutral
antibodi
extent
similar
freundsadjuv
suggest
addit
freund
adjuv
vaccin
formul
littl
advantag
improv
neutral
antibodi
respons
immun
mice
figur
contrast
note
protein
formul
alum
mplasm
especi
significantli
increas
titer
neutral
antibodi
among
five
adjuv
evalu
mplasm
freund
appear
repres
second
least
potent
one
respect
promot
product
neutral
antibodi
immun
mice
expect
identifi
neutral
antibodi
sera
obtain
mockimmun
mice
figur
superior
capac
trigger
highli
promin
neutral
antibodi
respons
compar
adjuv
test
believ
usag
merscov
protein
develop
achiev
optim
merscov
rbd
proteinbas
vaccin
strategi
evalu
protect
immun
merscov
rbd
presenc
adjuv
immun
mice
merscov
protein
plu
transduc
measur
viru
titer
lung
challeng
shown
figur
merscov
detect
lung
mice
immun
plu
day
postinfect
high
titer
viru
found
mice
inocul
pb
plu
adjuv
suggest
presenc
adjuv
merscov
rbd
highli
effect
protect
mice
merscov
challeng
thu
ideal
adjuv
use
merscov
rbd
proteinbas
subunit
vaccin
believ
combin
develop
achiev
optim
merscov
rbd
proteinbas
vaccin
strategi
base
immunogen
immun
laboratori
anim
recent
identifi
fragment
compos
residu
merscov
rbd
ideal
candid
vaccin
develop
uniqu
specif
fragment
contain
stabli
fold
rbd
structur
fulli
encompass
essenti
receptor
bind
site
possess
major
neutral
epitop
within
region
also
known
adjuv
play
import
role
improv
subunit
vaccin
efficaci
select
excel
adjuv
allow
optim
immun
respons
subunit
vaccin
candid
therefor
main
object
studi
identifi
ideal
adjuv
formul
merscov
rbdbase
subunit
protein
residu
report
use
recombin
protein
contain
residu
merscov
rbd
fuse
fc
human
igg
evalu
sever
adjuv
fc
fusion
protein
chosen
fc
may
enhanc
immunogen
target
antigen
compar
nonfc
fusion
protein
promot
correct
fold
fusion
protein
bind
antigenpres
cell
apc
express
fc
previous
shown
fcfuse
target
antigen
includ
envelop
glycoprotein
sever
acut
respiratori
syndrom
coronaviru
sarscov
influenza
virus
superior
lack
fusion
present
data
indic
absenc
adjuv
immun
mice
fusion
protein
result
induct
readili
detect
merscov
igg
antibodi
neutral
antibodi
well
cellmedi
immun
respons
suggest
fusion
fc
fragment
enhanc
immunogen
one
may
question
whether
mous
antihuman
igg
fc
antibodi
induc
human
fccontain
antigen
primari
immun
suppress
adjuvant
fc
fragment
fcfuse
rbd
protein
secondari
tertiari
immun
previou
current
studi
observ
immun
respons
secondari
tertiari
immun
alway
much
higher
primari
immun
figur
suggest
potenti
suppress
effect
preexist
mous
antihuman
fc
antibodi
present
neglig
similarli
onchocerca
volvulu
activationassoci
secret
proteinbas
adjuv
abl
induc
antiself
antibodi
vaccin
previou
studi
shown
preexist
mous
induc
primari
immun
signific
impact
adjuvant
subsequ
anoth
concern
use
fc
fragment
enhanc
immunogen
regulatori
tcell
epitop
igg
fc
may
activ
natur
regulatori
cell
result
toler
immun
respons
de
groot
et
demonstr
antihdm
dermatophagoid
pteronyssinu
antibodi
titer
hla
transgen
mice
reduc
hdm
antigen
coadminist
regulatori
tcell
epitop
murin
igg
fc
although
observ
immunotoler
induc
fc
fragment
protein
immun
period
investig
potenti
fc
fragment
protein
induc
immunotoler
hla
transgen
mice
warrant
adjuv
promot
immun
respons
mediat
proteinbas
vaccin
stabil
antigen
conform
target
antigen
apc
direct
antigen
present
major
histocompat
complex
class
ii
respons
stimul
cell
modul
antibodi
specif
isotyp
particular
increas
immunogen
merscov
rbd
protein
select
sever
commonli
use
adjuv
field
vaccinolog
freund
alum
mplasm
formul
panel
recombin
protein
vaccin
potenti
mechan
action
adjuv
notabl
differ
alum
exampl
mainli
stimul
innat
immun
promot
antigen
uptak
present
upregul
major
histocompat
complex
class
ii
molecul
induc
cell
mediat
bcell
differenti
secret
subtyp
ige
mpla
agonist
suppress
inflammatori
immun
respons
stimul
promot
monocyt
produc
mpla
function
bia
toward
tollinterleukin
receptor
domaincontain
adapt
induc
adjuv
report
increas
antigen
uptak
apc
induc
local
immunostimulatori
environ
recruit
key
immun
cell
mhc
class
ii
cell
inject
site
enhanc
transport
antigen
lymph
may
also
promot
earli
tcell
respons
allow
better
recal
respons
longterm
persist
protect
antibodi
present
studi
immun
mice
protein
formul
individu
aforement
adjuv
follow
comparison
result
merscovspecif
total
neutral
antibodi
cellmedi
respons
inde
found
immun
respons
could
improv
incorpor
adjuv
formul
adjuv
induc
high
level
antibodi
strong
neutral
activ
figur
suggest
antibodi
respons
may
play
role
inhibit
merscov
infect
howev
could
exclud
possibl
antibodi
may
play
domin
role
neutral
merscov
infect
report
main
subclass
induc
west
nile
viru
infect
human
account
vitro
neutral
observ
similar
phenomenon
studi
merscov
infect
exampl
mplasmadjuv
rbd
induc
significantli
lower
antibodi
rbd
figur
antibodi
group
exhibit
equal
potent
neutral
activ
figur
therefor
studi
issu
warrant
unlik
adjuv
test
promot
rapid
increas
igg
antibodi
two
immun
protein
antibodi
level
significantli
increas
boost
figur
suggest
two
dose
immun
suffici
adjuv
use
result
clearli
show
potent
induc
antimerscov
antibodi
neutral
activ
figur
furthermor
immun
merscov
rbd
plu
result
rapid
viru
clearanc
mice
challeng
merscov
figur
previou
studi
sarscov
anoth
caus
worldwid
outbreak
demonstr
although
cellular
immun
respons
also
effect
clear
sarscov
antibodi
respons
particularli
neutral
antibodi
play
critic
role
protect
immun
mice
challeng
shown
higher
neutral
titer
correl
greater
protect
sarscov
therefor
like
similar
sar
merscov
rbdinduc
antibodi
respons
particularli
neutral
antibodi
essenti
prevent
recoveri
merscov
infect
previou
report
sarscov
demonstr
sever
adjuv
includ
freund
sigma
adjuv
system
mplatdm
trehalos
dicorynomycoi
promot
rbd
protein
induct
strong
antibodi
respons
neutral
indic
adjuv
function
effici
formul
sarscov
rbdbase
subunit
vaccin
note
freund
adjuv
sigma
adjuv
system
suitabl
research
approv
use
human
thu
limit
applic
viru
infect
clinic
trial
report
variou
adjuv
may
side
effect
immun
mice
leenaar
et
compar
side
effect
five
differ
oilbas
adjuv
includ
freund
adjuv
specol
ribi
titermax
montanid
mice
adjuv
administ
peptid
antigen
subcutan
found
freund
adjuv
titermax
caus
signific
inflammatori
reaction
patholog
chang
inject
site
subcutan
administr
ribi
result
signific
increas
cytokin
mous
spleen
alum
shown
enhanc
inflamm
experiment
coliti
addit
mpla
report
induc
transient
inflamm
mice
intranas
present
studi
observ
mild
inflammatori
reaction
inject
site
mice
immun
merscov
rbdbase
subunit
vaccin
presenc
alum
freund
adjuv
appar
side
effect
mice
immun
rbd
protein
plu
adjuv
observ
compar
adjuv
alum
freund
mpla
uniqu
characterist
oilinwat
emuls
adjuv
activ
nontlr
sens
receptor
first
adjuv
licens
human
use
alum
superior
alum
adjuv
induc
antibodi
respons
antigen
virus
hiv
hbv
hcv
influenza
effect
safe
vaccin
adjuv
approv
europ
use
influenza
unlik
alum
vaccin
adjuv
wide
use
clinic
trial
influenza
vaccin
particularli
outbreak
influenza
demonstr
high
safeti
profil
strong
immunogen
enhanc
broaden
protect
influenza
viru
strong
efficaci
potenti
immunogen
influenza
viru
antigen
allow
antigen
dose
spare
abl
increas
seroconvers
crossprotect
vaccin
two
therefor
pandem
influenza
vaccin
priorit
sinc
antigen
dosespar
enhanc
crossreact
antibodi
titer
critic
event
pandem
show
although
mplasmadjuv
merscov
rbd
protein
also
induc
stronger
neutral
antibodi
merscov
infect
adjuv
test
figur
efficaci
significantli
lower
figur
moreov
adjuv
seen
elicit
modest
effect
antibodi
respons
hiv
caus
inflamm
mice
discuss
make
less
appeal
summari
data
demonstr
fcfuse
merscov
rbd
protein
induc
highli
potent
specif
immun
respons
formul
adjuv
suggest
ideal
adjuv
merscov
rbdbase
subunit
vaccin
present
studi
also
provid
foundat
evalu
adjuvant
subunit
vaccin
influenza
virus
virus
class
fusion
protein
hiv
sarscov
ebola
viru
nipah
viru
handra
viru
